Marta Santisteban Eslava-rekin lankidetzan egindako argitalpenak (7)

2024

  1. Prognostic value of systemic inflammation response indexes obtained from the complete blood count in patients treated for advanced ovarian carcinoma in front line

    Clinical and Translational Oncology

2021

  1. Final results regarding the addition of dendritic cell vaccines to neoadjuvant chemotherapy in early HER2-negative breast cancer patients: clinical and translational analysis

    Therapeutic Advances in Medical Oncology, Vol. 13

2020

  1. Complete cytoreductive surgery, the key factor for survival in advanced ovarian cancer. Experience of an intermediate volume hospital

    European Journal of Gynaecological Oncology, Vol. 41, Núm. 6, pp. 906-912

  2. The impact of secondary cytoreductive surgery on survival in first recurrence of platinum sensitive epithelial ovarian cancer

    European Journal of Gynaecological Oncology, Vol. 41, Núm. 4, pp. 523-530

2018

  1. Erratum: Perioperative high-dose-rate brachytherapy in locally advanced and recurrent gynecological cancer: Final results of a Phase II trial (Brachytherapy (2018) 17(5) (734–741), (S1538472118300898) (10.1016/j.brachy.2018.04.007))

    Brachytherapy

  2. Perioperative high-dose-rate brachytherapy in locally advanced and recurrent gynecological cancer: Final results of a Phase II trial

    Brachytherapy, Vol. 17, Núm. 5, pp. 734-741

2016

  1. Multicatheter breast implant during breast conservative surgery: Novel approach to deliver accelerated partial breast irradiation

    Brachytherapy, Vol. 15, Núm. 4, pp. 485-494